Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Ponatinib (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 18 Jul 2017 Status changed from recruiting to suspended.
- 10 Jun 2017 Biomarkers information updated
- 23 Dec 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.